Two Hepatitis B Drugs Granted Breakthrough Therapy Designation; Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rises 2.70% Intraday

NewTimeSpace News: As of 9:55 on October 28, 2026, Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) rose 2.70% intraday to a latest price of HK$14.450, with a turnover of HK$41.29 million, a trading volume of 2.87 million shares, and a turnover rate of 1.30%. Its current net asset value per unit is HK$14.1552, and its assets under management stand at HK$3.12 billion.

NewTimeSpace understands that Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) is managed by China Asset Management (Hong Kong), with the full name ChinaAMC Hang Seng Biotech ETF, and an investment objective of providing investment returns that closely track the Hang Seng Hong Kong-Listed Biotech Index, before fees and expenses. The ETF primarily adopts a full replication strategy, investing directly in securities within the Index in weightings broadly the same as their weightings in the Index; where restrictions or limited availability prevent the purchase of certain constituents, it will adopt a representative sampling strategy, under which the maximum deviation of any constituent from its Index weighting does not exceed 4%. The ETF may invest up to 5% of net asset value in money market instruments and cash deposits for cash management purposes; non-constituent securities held as a result of corporate actions by Index constituents are capped at 10% of net asset value; and it currently has no intention to use financial derivative instruments for hedging or investment purposes. The fund was established and listed on the Stock Exchange of Hong Kong on March 18, 2021, with a management fee of 0.40%. As of October 27, the ETF had assets under management of HK$3.12 billion and a net asset value per unit of HK$14.1552.

On the news front, SBP GROUP (01177.HK) announced on October 27 that two Class 1 innovative drugs independently developed by its subsidiary Chia Tai Tianqing have both been granted breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration; the two drugs target functional cure and low-level viraemia in chronic hepatitis B respectively, with one already in Phase III trials and the other about to enter Phase III. SBP GROUP is a constituent of the Hang Seng Hong Kong-Listed Biotech Index.

FIN STREET SEC believes that, as of October 21, 2026, the SHS Innovative Drug Index traded at a PE-TTM of 28.57x, in the 79.54% percentile over the past five years and already at its danger threshold of 28.54x, having recovered about 63% from its five-year low of 17.57x—no longer cheap on a static basis. Interim 2026 net profit attributable to shareholders grew 47.38% year-on-year, with a number of biotech companies turning profitable in bulk, and as the trailing twelve-month earnings base rises, the dynamic price-earnings ratio will shift lower accordingly. The broker accordingly judges that further upside for the sector will depend more on earnings delivery than on valuation expansion.